{"id":1776,"date":"2022-01-24T10:00:19","date_gmt":"2022-01-24T09:00:19","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=1776"},"modified":"2022-01-24T10:02:07","modified_gmt":"2022-01-24T09:02:07","slug":"advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/","title":{"rendered":"Advanced melanoma, encouraging results with relatlimab e nivolumab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Together with the PD-1 inhibitor nivolumab relatlimab, a novel antibody that blocks an immune checkpoint found on the surface of T cells, offers benefit in patients with advanced melanoma: as shown in <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2109970\" target=\"_blank\" rel=\"noopener\">a paper on New England Journal of Medicine<\/a>,\u00a0 progression-free survival rates were 47.7% in the combination therapy arm versus 36% in the nivolumab monotherapy arm.<\/p>\n<p>The international, multicentric phase II\/III Relativity-047 clinical trial enrolled 714 patients with untreated, unresectable stage III or IV melanoma. Patients were randomized to receive a fixed dose combination of relatlimab and nivolumab or nivolumab alone intravenously every four weeks. At the time of data cutoff in March 2021, median follow-up was more than 13 months, with 65.8% of patients having discontinued treatment mostly because of disease progression (36.3% in the combination arm vs 46% in the monotherapy arm). The progression-free survival rates were 47.7% in the combination arm versus 36% in the monotherapy arm, with a 25% lower risk of disease progression or death in the combination arm. Treatment-related adverse events occurred more frequently in the combination arm (18.9% vs. 9.7% in the monotherapy arm) but no new safety signals were identified and safety profile was manageable, with no differences in health-related quality of life across both treatment arms.<\/p>\n<p>Lead author Hussein Twabi, MD Anderson Cancer Center, said: \u00abThe results from this global effort advance the field of immunotherapy by establishing a third class of immune checkpoint inhibitors through the LAG-3 pathway (lymphocyte-activation gene 3, an immune checkpoint on T cells, ed.) and have the potential to be practice-changing. We\u2019ve seen historic developments in melanoma treatment over the last decade with the combination of PD-1 and CTLA-4 inhibitors, which work well but also carry substantial toxicity. This study represents a significant and long-awaited next step toward providing patients with effective and safer treatment options\u00bb. The Food and Drug Administration granted priority review to the combination in September 2021 based on the results of Relativity-047 study. \u00abWe now have evidence of a clear benefit for combination therapy compared to single-agent PD-1 inhibitors, regardless patient subgroups (such as tumor stage or PD-1 and LAG-3 expression, ed.), and we\u2019re looking forward to seeing response and overall survival data\u00bb, said Tawbi.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;1773&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Together with the PD-1 inhibitor nivolumab relatlimab,<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":1773,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-1776","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-24T09:00:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-24T09:02:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Advanced melanoma, encouraging results with relatlimab e nivolumab\",\"datePublished\":\"2022-01-24T09:00:19+00:00\",\"dateModified\":\"2022-01-24T09:02:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/\"},\"wordCount\":426,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_261932205.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/\",\"name\":\"Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_261932205.jpg\",\"datePublished\":\"2022-01-24T09:00:19+00:00\",\"dateModified\":\"2022-01-24T09:02:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_261932205.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_261932205.jpg\",\"width\":1500,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advanced melanoma, encouraging results with relatlimab e nivolumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna","description":"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/","og_locale":"en_US","og_type":"article","og_title":"Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna","og_description":"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2022-01-24T09:00:19+00:00","article_modified_time":"2022-01-24T09:02:07+00:00","og_image":[{"width":1500,"height":1000,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Advanced melanoma, encouraging results with relatlimab e nivolumab","datePublished":"2022-01-24T09:00:19+00:00","dateModified":"2022-01-24T09:02:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/"},"wordCount":426,"commentCount":0,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/","name":"Advanced melanoma, encouraging results with relatlimab e nivolumab - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg","datePublished":"2022-01-24T09:00:19+00:00","dateModified":"2022-01-24T09:02:07+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"In patients with untreated, advanced melanoma, the combination of two immune checkpoint inhibitors increase progression-free survival","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_261932205.jpg","width":1500,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/advanced-melanoma-encouraging-results-with-relatlimab-e-nivolumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Advanced melanoma, encouraging results with relatlimab e nivolumab"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=1776"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1776\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/1773"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=1776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=1776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=1776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}